

2022-9 Nrf2 Activators and Covid-19

Both Adaptogens and some polyphenols can activate the nuclear factor erythroid-2-related factor 2 (Nrf2) pathway, For example, Amla, *Emblica officinalis*, is an adaptogen that activates the Nrf2 pathway. The pathway removes cellular trash, misfolded proteins, both organic and inorganic xenobiotics, such as parts of viruses and toxic metals. It fixes or restores you energy producing mitochondria and restore life to cells by activating telomerase to lengthen their telomeres. It makes you feel young again. Adaptogens help with mental and physical stress. A regular diet of adaptogens can enable rats and people to swim twice as long before they drown. Adaptogens help recovery from any sickness.

Antiviral

Review

Pharmaceuticals (Basel)

actions:

. 2020 Sep 8;13(9):236. doi: 10.3390/ph13090236.

The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections

[Alexander Panossian](#) 1 2, [Thomas Brendler](#) 3 4 5

Affiliations collapse

Affiliations

- 1
Phytomed AB, Vaxtorp, 31275 Halland, Sweden.
- 2
EuropharmaUSA, Green Bay, WI 54311, USA.
- 3
Department of Botany and Plant Biotechnology, University of Johannesburg, Johannesburg 2000, South Africa.
- 4
Traditional Medicinals Inc., Rohnert Park, CA 94928, USA.
- 5
Plantaphile, Collingswood, NJ 08108, USA.

- PMID: 32911682 PMCID: [PMC7558817](#) DOI: [10.3390/ph13090236](#)

[Free PMC article](#)

[Full text links](#) [Cite](#)

Abstract

The aim of our review is to demonstrate the potential of herbal preparations, specifically adaptogens for prevention and treatment of respiratory infections, as well as convalescence, specifically through supporting a challenged immune system, increasing resistance to viral infection, inhibiting severe inflammatory progression, and driving effective recovery. The evidence from pre-clinical and clinical studies with *Andrographis paniculata*, *Eleutherococcus senticosus*, *Glycyrrhiza* spp., *Panax* spp., *Rhodiola rosea*, *Schisandra chinensis*, ***Withania somnifera***, their combination products and melatonin suggests that [adaptogens can be useful in prophylaxis and treatment of viral infections at all stages of progression of inflammation as well as in aiding recovery of the organism by \(i\) modulating innate and adaptive immunity, \(ii\) anti-inflammatory activity, \(iii\) detoxification and repair of oxidative stress-induced damage in compromised cells, \(iv\) direct antiviral effects of inhibiting viral docking or replication, and \(v\) improving quality of life during convalescence.](#)

Keywords: Andrographis; Eleutherococcus; Glycyrrhiza; Panax; Rhodiola; Schisandra; Withania; adaptogens; melatonin; viral infection.

Conflict of interest statement

The authors declare no conflict of interest.

[Sheng Li Xue Bao](#)

actions:

. 2015 Feb 25;67(1):1-18.

***Emblica officinalis*, a master regulator of detoxification and also antioxidant, anti-inflammatory and other cytoprotective mechanisms, is raised by health promoting factors**

[Martin L Pall](#) ¹, [Stephen Levine](#) ²

Affiliations

- 1
Washington State University, Portland, Oregon 97232-3312, USA.
martin_pall@wsu.edu.
- 2
Allergy Research Group, Alameda, California 94502, USA.
- PMID: 25672622

Free article

Abstract

The transcription factor Nrf2, nuclear factor erythroid-2-related factor 2, activates the transcription of over 500 genes in the human genome, most of which have cytoprotective functions. Nrf2 produces cytoprotection by detoxification mechanisms leading to increased detoxification and excretion of both organic xenobiotics and toxic metals; its action via over two dozen genes increases highly coordinated antioxidant activities; it produces major anti-inflammatory changes; it stimulates mitochondrial biogenesis and otherwise improves mitochondrial function; and it stimulates autophagy, removing toxic protein aggregates and dysfunctional organelles. Health-promoting nutrients and other factors act, at least in part by raising Nrf2 including: many phenolic antioxidants; gamma- and delta-tocopherols and tocotrienols; long chain omega-3 fatty acids DHA and EPA; many carotenoids of which lycopene may be the most active; isothiocyanates from cruciferous vegetables; sulfur compounds from allium vegetables; terpenoids. Other health promoting, Nrf2 raising factors include low level oxidative stress (hormesis), exercise and caloric restriction. **Raising Nrf2 has been found to prevent and/or treat a large number of chronic inflammatory diseases in animal models and/or humans including various cardiovascular diseases, kidney diseases, lung diseases, diseases of toxic liver damage, cancer (prevention), diabetes/metabolic syndrome/obesity, sepsis, autoimmune diseases, inflammatory bowel disease, HIV/AIDS and epilepsy. Lesser evidence suggests that raising Nrf2 may lower 16 other diseases. Many of these diseases are probable NO/ONOO(-) cycle diseases and Nrf2 lowers effects of NO/ONOO(-) cycle elements. **The most healthful diets known, traditional Mediterranean and Okinawan, are rich in Nrf2 raising nutrients as apparently was the Paleolithic diet that our ancestors ate. Modern diets are deficient in such nutrients.** Nrf2 is argued to be **both lifespan****

and health-span extending. Possible downsides to too much Nrf2 are also discussed. Nrf2 is not a magic bullet but is likely to be of great importance in health promotion, particularly in those regularly exposed to toxic chemicals.

Dr. Bill's summary:

Amla causes the transcription factor Nrf2, nuclear factor erythroid-2-related factor 2, to activate the transcription of over 500 genes, which is almost 4% of the estimated 25,000 human genes. This causes cells to produce hundreds of enzymes with cytoprotective functions. Raising Nrf2 has been found to prevent and/or treat a large number of chronic inflammatory diseases. Currently drug companies are trying to produce drugs that can do what Amla can do to the structure and function of cells.

[Review](#)

[Trends Food Sci Technol](#)

actions:

. 2021 Aug;114:11-24. doi: 10.1016/j.tifs.2021.05.023. Epub 2021 May 25.

Potential protective mechanisms of green tea polyphenol EGCG against COVID-19

[Zhichao Zhang](#) ¹, [Xiangchun Zhang](#) ², [Keyi Bi](#) ³, [Yufeng He](#) ³, [Wangjun Yan](#) ¹, [Chung S Yang](#) ⁴, [Jinsong Zhang](#) ³

Affiliations collapse

[Free PMC article](#)

[Full text links](#) [Cite](#)

Abstract

Background: The world is in the midst of the COVID-19 pandemic. In this comprehensive review, we discuss the potential protective effects of (-)-epigallocatechin-3-gallate (EGCG), a major constituent of green tea, against COVID-19.

Scope and approach: Information from literature of clinical symptoms and molecular pathology of COVID-19 as well as relevant publications in which EGCG shows potential protective activities against COVID-19 is integrated and evaluated.

Key findings and conclusions: EGCG, via activating Nrf2, can suppress ACE2 (a cellular receptor for SARS-CoV-2) and TMPRSS2, which mediate cell entry of the virus. **Through inhibition of SARS-CoV-2 main protease, EGCG may inhibit viral reproduction.** EGCG via its broad antioxidant activity may protect against SARS-CoV-2 evoked mitochondrial ROS (which promote SARS-CoV-2 replication) and against ROS burst inflicted by neutrophil extracellular traps. **By suppressing ER-resident GRP78 activity and expression, EGCG can potentially inhibit SARS-CoV-2 life cycle.** EGCG also shows protective effects against 1) cytokine storm-associated acute lung injury/acute respiratory distress syndrome, 2) thrombosis via suppressing tissue factors and activating platelets, 3) sepsis by inactivating redox-sensitive HMGB1, and 4) lung fibrosis through augmenting Nrf2 and suppressing NF- κ B. These activities remain to be further substantiated in animals and humans. The possible concerted actions of EGCG suggest the importance of further studies on the prevention and treatment of COVID-19 in humans. These results also call for epidemiological studies on potential preventive effects of green tea drinking on COVID-19.

Keywords: COVID-19; EGCG; Prevention; SARS-CoV-2; Tea; Treatment.
© 2021 Elsevier Ltd. All rights reserved.

Conflict of interest statement

The authors declare no conflict of interest.

Review

[Trends Pharmacol Sci](#)

actions:

. 2020 Sep;41(9):598-610. doi: 10.1016/j.tips.2020.07.003. Epub 2020 Jul 14.

Can Activation of NRF2 Be a Strategy against COVID-19?

[Antonio Cuadrado](#) ¹, [Marta Pajares](#) ², [Cristina Benito](#) ², [José Jiménez-Villegas](#) ², [Maribel Escoll](#) ², [Raquel Fernández-Ginés](#) ², [Angel J Garcia Yagüe](#) ², [Diego Lastra](#) ², [Gina Manda](#) ³, [Ana I Rojo](#) ², [Albena T Dinkova-Kostova](#) ⁴

Affiliations collapse

- PMID: 32711925 PMCID: [PMC7359808](#) DOI: [10.1016/j.tips.2020.07.003](#)

Free PMC article

Full text links Cite

Abstract

Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (leukopenia) characterize the most aggressive presentation. We propose that a multifaceted anti-inflammatory strategy based on pharmacological activation of nuclear factor erythroid 2 p45-related factor 2 (NRF2) can be deployed against the virus. **The strategy provides robust cytoprotection by restoring redox and protein homeostasis, promoting resolution of inflammation, and facilitating repair. NRF2 activators such as sulforaphane and bardoxolone methyl are already in clinical trials. The safety and efficacy information of these modulators in humans, together with their well-documented cytoprotective and anti-inflammatory effects in preclinical models, highlight the potential of this armamentarium for deployment to the battlefield against COVID-19.**

Keywords: KEAP1; SARS-CoV-2; anti-inflammatory ARDS; bardoxolone methyl; sulforaphane.

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Review

Free Radic Biol Med

actions:

. 2021 May 28;S0891-5849(21)00325-7. doi: 10.1016/j.freeradbiomed.2021.05.033. Online ahead of print.

Nrf2 Activator PB125® as a Carnosic Acid-Based Therapeutic Agent against Respiratory Viral Diseases, including COVID-19

[Joe M McCord](#) ¹, [Brooks M Hybertson](#) ², [Adela Cota-Gomez](#) ³, [Bifeng Gao](#) ⁴

Affiliations expand

- PMID: 34058321 DOI: [10.1016/j.freeradbiomed.2021.05.033](https://doi.org/10.1016/j.freeradbiomed.2021.05.033)

Full text links Cite

Abstract

PB125® is a phytochemical composition providing potent Nrf2 activation as well as a number of direct actions that do not involve Nrf2. Nrf2 is a transcription actor that helps maintain metabolic balance by providing redox-sensitive expression of numerous genes controlling normal day-to-day metabolic pathways. When ordinary metabolism is upset by extraordinary events such as injury, pathogenic infection, air or water pollution, ingestion of toxins, or simply by the slow but incessant changes brought about by aging and genetic variations, Nrf2 may also be called into action by the redox changes resulting from these events, whether acute or chronic. A complicating factor in all of this is that Nrf2 levels decline with aging, leaving the elderly less able to maintain proper redox balance. The dysregulated gene expression that results can cause or exacerbate a wide variety of pathological conditions, including susceptibility to viral infections.

This review examines the characteristics desirable in Nrf2 activators that have therapeutic potential, as well as some of the patterns of dysregulated gene expression commonly observed during pulmonary infections and the normalizing effects possible by judicious use of phytochemicals to increase the activation level of available Nrf2.

Keywords: COVID-19; Nrf2; PB125; SARS-CoV-2; carnosic acid; coronavirus; cytokines; endothelium; interferon.

Copyright © 2021. Published by Elsevier Inc.

[Nat Commun](#)

actions:

. 2020 Oct 2;11(1):4938. doi: [10.1038/s41467-020-18764-3](https://doi.org/10.1038/s41467-020-18764-3).

SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate

[David OLAGNIER](#) ¹, [Ensieh Farahani](#) ², [Jacob Thyrsted](#) ², [Julia Blay-Cadanet](#) ², [Angela Herengt](#) ², [Manja Idorn](#) ², [Alon Hait](#) ² ³, [Bruno Hernaez](#) ⁴, [Alice Knudsen](#) ², [Marie Beck Iversen](#) ², [Mirjam Schilling](#) ⁵, [Sofie E Jørgensen](#) ² ³, [Michelle Thomsen](#) ² ³, [Line S Reinert](#) ², [Michael Lappe](#) ⁶, [Huy-Dung Hoang](#) ⁷, [Victoria H Gilchrist](#) ⁷, [Anne Louise Hansen](#) ², [Rasmus Ottosen](#) ⁸, [Camilla G Nielsen](#) ², [Charlotte Møller](#) ², [Demi van der Horst](#) ², [Suraj Peri](#) ⁹, [Siddharth Balachandran](#) ⁹, [Jinrong Huang](#) ¹⁰ ¹¹, [Martin Jakobsen](#) ², [Esben B Svenningsen](#) ⁸, [Thomas B Poulsen](#) ⁸, [Lydia Bartsch](#) ¹², [Anne L Thielke](#) ², [Yonglun Luo](#) ² ¹⁰, [Tommy Alain](#) ⁷, [Jan Rehwinkel](#) ⁵, [Antonio Alcamí](#) ⁴, [John Hiscott](#) ¹³, [Trine H Mogensen](#) ² ³ ¹⁴, [Søren R Paludan](#) ², [Christian K Holm](#) ¹⁵

Affiliations

- ¹
School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
- ²
Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
- ³
Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
- ⁴
GlaxoSmithKline, Gunnelswood Road, Stevenage, Hertfordshire, UK.
- ⁵
MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK.
- ⁶
Jacqui Wood Cancer Centre, Division of Cancer Research, School of Medicine, University of Dundee, Dundee DD1 9SY, UK.
- ⁷
MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, UK.

- 8
School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
- 9
School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
- 10
Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Oxford OX3 7FZ, UK.
- 11
Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee DD1 9SY, UK.
- 12
GlaxoSmithKline, Park Road, Ware, Hertfordshire, UK.
- 13
Cellzome, GlaxoSmithKline R&D, Heidelberg, Germany.
- 14
WestCHEM School of Chemistry, University of Glasgow, Glasgow G12 8QQ, UK.
- 15
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
-
- PMID: 33009401 PMCID: [PMC7532469](#) DOI: [10.1038/s41467-020-18764-3](#)

Free PMC article

Full text links Cite

- Nat Commun. 2020 Oct 21;11(1):5419. doi: 10.1038/s41467-020-19363-y.
PMID: 33087717 **Free PMC article.**

Abstract

Antiviral strategies to inhibit Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the pathogenic consequences of COVID-19 are urgently required. Here, we demonstrate that the NRF2 antioxidant gene expression pathway is suppressed in biopsies obtained from COVID-19 patients. Further, we uncover that NRF2 agonists 4-octyl-itaconate (4-OI) and the clinically approved dimethyl

fumarate (DMF) induce a cellular antiviral program that potently inhibits replication of SARS-CoV2 across cell lines. The inhibitory effect of 4-OI and DMF extends to the replication of several other pathogenic viruses including Herpes Simplex Virus-1 and-2, Vaccinia virus, and Zika virus through a type I interferon (IFN)-independent mechanism. In addition, 4-OI and DMF limit host inflammatory responses to SARS-CoV2 infection associated with airway COVID-19 pathology. In conclusion, **NRF2 agonists 4-OI and DMF induce a distinct IFN-independent antiviral program that is broadly effective in limiting virus replication and in suppressing the pro-inflammatory responses of human pathogenic viruses, including SARS-CoV2.**

Conflict of interest statement

The authors declare no competing interests.

Most of the good phenols have been removed from the food we eat today.

[Am J Clin Nutr](#)

actions

. 2000 Dec;72(6):1424-35. doi: 10.1093/ajcn/72.6.1424.

Bitter taste, phytonutrients, and the consumer: a review

[A Drewnowski](#) ¹, [C Gomez-Carneros](#)

Affiliations collapse

1. Nutritional Sciences Program, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA.

• PMID: 11101467 DOI: [10.1093/ajcn/72.6.1424](#)

[Full text links Cite](#)

Abstract

Dietary phytonutrients found in vegetables and fruit appear to lower the risk of cancer and cardiovascular disease. Studies on the mechanisms of chemoprotection have focused on the biological activity of plant-based phenols and polyphenols, flavonoids, isoflavones, terpenes, and glucosinolates. Enhancing the

phytonutrient content of plant foods through selective breeding or genetic improvement is a potent dietary option for disease prevention. However, most, if not all, of these bioactive compounds are bitter, acrid, or astringent and therefore aversive to the consumer. Some have long been viewed as plant-based toxins. As a result, the food industry routinely removes these compounds from plant foods through selective breeding and a variety of debittering processes. This poses a dilemma for the designers of functional foods because increasing the content of bitter phytonutrients for health may be wholly incompatible with consumer acceptance. Studies on phytonutrients and health ought to take sensory factors and food preferences into account.